Surveillance for Onchocerciasis-Associated Epilepsy and OV16 IgG4 Testing of Children 6–10 Years Old Should Be Used to Identify Areas Where Onchocerciasis Elimination Programs Need Strengthening

Surveillance for Onchocerciasis-Associated Epilepsy and OV16 IgG4 Testing of Children 6–10 Years Old Should Be Used to Identify Areas Where Onchocerciasis Elimination Programs Need Strengthening

To eliminate onchocerciasis-associated morbidity, it is important to identify areas where there is still high ongoing <i>Onchocerca volvulus</i> transmission. Between 2015 and 2021, door-to-door surveys were conducted in onchocerciasis-endemic villages in Cameroon, the Democratic Republi...

Täydet tiedot

Bibliografiset tiedot
Päätekijät: Alfred Dusabimana, Joseph Nelson Siewe Fodjo, Michel Mandro Ndahura, Bruno P. Mmbando, Stephen Raimon Jada, Annelies Boven, Eric De Smet, Tony Ukety, Alfred K. Njamnshi, Anne Laudisoit, Steven Abrams, Robert Colebunders
Aineistotyyppi: Artikkeli
Kieli:English
Julkaistu: MDPI AG 2022-02-01
Sarja:Pathogens
Aiheet:
onchocerciasis
onchocerciasis-associated epilepsy
epilepsy prevalence
incidence
ivermectin
OV16 antibodies
Linkit:https://www.mdpi.com/2076-0817/11/3/281

Samankaltaisia teoksia

Samankaltaisia teoksia